Clarification from GSK on the supply of Boostrix
Following a number of media reports over the Easter long weekend, GlaxoSmithKline (GSK) Pharmaceuticals has contacted the AMA to confirm that there is no supply interruption of Boostrix to the National Immunisation Program (NIP) or any state based vaccination programs for which Boostrix is being supplied.
GSK advises that although private market supply of Boostrix at GP and pharmacy level (outside of the NIP and state-based vaccination programs) may have been impacted by temporary disruptions in the past six months, there is currently supply of Boostrix at all wholesalers. GSK continues to monitor and manage the supply of Boostrix to the private market, with priority being given to the NIP and state-based vaccination programs.
GSK advises there is a shortage of Boostrix®-IPV (Diptheria, Tetanus, Pertussis and Polio vaccine) vaccine anticipated until July 2015, as stated on the Therapeutic Goods Administration website. This issue is specific to Boostrix-IPV only, and does not impact the supply of Boostrix to the NIP, state based vaccination programs or the private market. This supply constraint is not related to vaccine quality or safety.
